RecruitingNCT07257562

Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

A Prospective Observational Study on the Effects of Concomitant Administration of Bacteroides Fragilis and Branched-Chain Amino Acids on HBsAg Clearance


Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

40 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • \- chronic hepatitis B patients

Exclusion Criteria3

  • patients with malignancies
  • patients with other liver diseases
  • pregnancy patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPegIFNα2b+Nucleoside analog

The patients receive both PegIFNα2b and Nucleoside analog therapy.

DRUGPegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids

The patients received the concomitant administration of Bacteroides fragilis and BCAA, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.


Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07257562


Related Trials